Cure My Disease

Don't miss your cure!

 Log in / Sign up

Placenta cells tested as COVID fighter – but trial stopped early

NCT ID NCT04365101

Terminated Disease control Sponsor: Celularity Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new therapy called CYNK-001, which uses natural killer cells from the placenta to fight COVID-19. It enrolled only 7 adults with moderate COVID-19. The study was terminated early, so we have limited information on safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CYNK-001 (natural killer cells from placenta)

What this could lead to

If successful, this could point toward a cell-based therapy to help the immune system fight COVID-19.

What could go wrong

This was a very early, small trial (only 7 people) that was terminated early, so results are limited. Cell therapies can have side effects like infusion reactions or immune system overactivation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome Coronavinae infectious disease Coronaviridae Infections Coronaviridae infectious disease COVID-19 immune system disorder lung disorder Nidovirales infectious disease pneumonia respiratory system disorder respiratory tract infectious disorder RNA Virus Infections viral infectious disease viral pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANALGESICS ANTI-INFECTIVE AGENTS ANTIMETABOLITES, ANTINEOPLASTIC ANTIVIRAL AGENTS ARDS CORONAVIRIDAE INFECTIONS CORONAVIRUS CORONAVIRUS INFECTION IMMUNOLOGIC DISEASE IMMUNOLOGIC FACTORS LUNG DISEASES NIDOVIRALES INFECTIONS PHYSIOLOGICAL EFFECTS OF DRUGS PNEUMONIA PNEUMONIA, VIRAL RESPIRATORY TRACT DISEASE RESPIRATORY TRACT INFECTIONS RNA VIRUS INFECTIONS SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 VIRUS DISEASE

Contacts and locations

Locations

  • Atlantic Health

    Morristown, New Jersey, 07960, United States

  • Atlantic Health

    Summit, New Jersey, 07901, United States

  • Multicare Health System

    Tacoma, Washington, 98405, United States

  • UC Irvine

    Irvine, California, 92697, United States